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LETTERS TO THE EDITOR
Recombinant Factor VIIa
to Treat Diffuse Alveolar
Hemorrhage following
Allogeneic Stem
Cell Transplantation
We report a female patient who developed volume
overload and diffuse pulmonary inﬁltrates on day 14
following a myeloablative stem cell transplant (SCT)
from an HLA identical sibling for acute myelogenous
leukemia (AML). Empiric antibiotics and antifungal
treatment was started immediately, but on day 16
she required intubation; diffuse alveolar hemorrhage
(DAH) was suspected and subsequently conﬁrmed by
bronchoscopy. Intravenous methylprednisolone, 100
mg daily, was started and ventilatory function im-
proved. However, on day 20 gas exchanges wors-
ened and a single 90 g/kg dose of recombinant factor
VIIa (rFVIIa) was given. Bronchoscopy the next day
conﬁrmed a further hemorrhage and another dose of
rFVIIa was administered 17 hours after the ﬁrst dose.
Her condition rapidly improved, and she was extu-
bated 4 days after the ﬁrst dose of rFVIIa. She is now
doing well 9 months posttransplantation.
Although DAH affects a minority of patients post-
transplant, it carries a high mortality. In a retrospec-
tive analysis of 60 SCT patients, DAH was the second
leading cause of respiratory failure (37%), with an
overall survival (OS) of 19% [1]. Although steroids,
transfusion support, and treatments directed at the
underlying condition (often infectious) remain the
mainstays of therapy, recent case reports document
success with Aminocaproic acid (Amicar) or rFVIIa.
Wanko et al [2] reviewed 14 patients who experi-
enced 15 episodes of DAH after SCT. All were
treated with steroids. Amicar, 1 g every 6 hours, was
given concurrently in 1 patient and following treat-
ment failure with steroids in 8. One hundred-day
mortality was 44% in Amicar recipients compared
to 83% for those receiving steroids alone; but 1
patient who received Amicar had a recurrent epi-
sode of DAH.
Recombinant FVIIa has been used with success to
treat severe bleeding in thrombocytopenic patients
[3-5]. Hicks et al [6] used rFVIIa to treat DAH after
failure of 9 days treatment with steroids, desmopressin
(DDAVP), fresh frozen plasma (FFP), and Amicar.
Hemorrhage stopped after 3 doses of rFVIIa 90 g/kg
given 3 hours apart, recurred 24 hours later, but re-
solved completely after a total of 24 doses of rFVIIa
were administered. Pastores et al [7] used rFVIIa 90
mg/kg every 2 hours in addition to standard therapy to
treat DAH within 6 hours of diagnosis, with resolu-
tion of bleeding after the second dose and extubation
6 days later. Blatt et al [8] used rFVIIa 90 g/kg every
6 hours, to treat a child with DAH, hemorrhagic
cystitis, and gastrointestinal bleeding post-SCT. Al-
though there was pulmonary improvement the patient
died of a massive gastrointestinal bleed.
Recombinant FVIIa, ﬁrst approved for treatment
of bleeding in patients with hemophilia A or B with
inhibitors, was initially thought to work by binding to
tissue factor and increasing effects through the extrin-
sic pathway; however, more recent in vitro data favors
a tissue factor-independent pathway. rFVIIa is postu-
lated to bind to activated platelets and activate factor
X, leading to thrombin generation independent of
tissue factor [9,10]. Additionally, given that this
thrombin burst is isolated to the surfaces of activated
platelets, effects of rFVIIa can be localized to the areas
of tissue injury with minimal systemic thrombogenic
side effects. Indeed, none of the cases reviewed doc-
umented any ill effects from rFVIIa despite repetitive
doses.
The half-life of rFVIIa is only 2.3 hours. Thus, to
be effective, frequent administration early in the
course of hemorrhage is needed. The literature cited
supports the use of a dose of 90 g/kg rFVIIa for
DAH, but the optimum dose and schedule of rFVIIa
remains to be elucidated.
These promising results from case reports suggest
that rFVIIa should be considered early in the course of
DAH. Although rFVIIa is an expensive treatment, the
cost of early administration with prompt resolution of
DAH could potentially be offset against a lengthy
period in intensive care. Controlled trials comparing
steroids with or without other treatments and rFVIIa
would be required to clearly identify the therapeutic
role of rFVIIa in DAH, but realistically, given the
rarity of the complication, such trials are unlikely to be
initiated.
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Autologous Stem Cell
Transplantation as Part
of First-Line Treatment
of Waldenstro¨m’s
Macroglobulinemia
In the August 2006 issue of BBMT, Anagnosto-
poulos and coworkers [1] reported superior outcome
of autologous (autoSCT, n 10) over allogeneic stem
cell transplantation (alloSCT, n  26) in 36 patients
with Waldenström’s macroglobulinemia (WM). Re-
ferring to data of our group, the authors discussed that
the results of autoSCT in WM might further be
improved by using this modality earlier during the
course of the disease. We would like to take the
opportunity to give an update of our approach, which
was originally published in 1999 [2].
WM patients were treated on subsequent prospec-
tive protocols aimed at investigating the feasibility and
efﬁcacy of autoSCT as part of ﬁrst-line treatment of
indolent lymphoma. The protocols, including the in-
formed consent forms, were approved by the respon-
sible institutional review board (Ethics Committee of
the University of Kiel). Patients gave written informed
consent using study-speciﬁc forms. Patients with
symptomatic disease were eligible if they were be-
tween 18 and 65 years old, had an adequate perfor-
mance status (Karnofsky 80%), and never received
WM-speciﬁc cytotoxic treatment. After an optional
initial cytoreduction with alkylators or ﬂudarabine,
patients were treated with 1-3 cycles of Dexa-BEAM
chemotherapy for stem cell mobilization and remis-
sion induction, followed by myeloablative therapy
with total body irradiation (TBI)/high-dose cyclo-
phosphamide and stem cell reinfusion. In the ﬁrst 5
patients, grafts were vigorously B cell-depleted by
immunomagnetic CD34 and/or negative B cell se-
lection [2].
Between March 1995 and September 2003, 12
consecutive patients fulﬁlling eligibility criteria were
included. Median age was 49 (39-61) years. Prior to
treatment, serum IgM levels were 46.7 (17.4-92.3)
g/L, and all patients had symptomatic disease because
of anemia, bulky lymphadenopathy, hyperviscosity,
and/or B symptoms. Four patients proceeded directly
to Dexa-BEAM mobilization, whereas the remainder
received 3-6 cycles of CHOP (4), R-CHOP (2),
chlorambucil (1), or ﬂudarabine (1) beforehand, re-
sulting in partial remission (5) or no response (3).
Mobilization failure did not occur. After myeloabla-
tive therapy and stem cell reinfusion (median CD34
cell number 5.3 (2.1-13.2) 106/kg), engraftment was
prompt, and toxic deaths did not occur. Although
autoSCT induced strong reduction or normalization
of serum IgM levels in all patients (5.4 [2.1-23.2] g/L
at 100 days posttransplant), immunoﬁxation remained
monoclonal in all but 2 patients, suggesting persis-
tence of residual disease. Disease progression was ob-
served in 6 patients, translating into a median progres-
sion-free survival of 69 months (Figure 1). Median
time to retreatment was 82 months, and all patients
are still alive after a median follow-up of 69 (25-123)
months after autoSCT.
In conclusion, these results show that ﬁrst-line
high-dose radiochemotherapy with autoSCT is
highly effective in patients with symptomatic WM.
Even though complete eradication of the disease
Letters to the Editor 623
